1/2상모집 중단 (진행 중)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

연구 개요

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

스폰서: 리드: 일라이 릴리 · 협력: 머크(MSD)
적응증: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
중재: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
목표 등록: 540명
시작일: 2021-07-19
완료(예정): 2027-04-01
등록번호: NCT04956640 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.